Evolving knowledge of the teratogenicity of medications in human pregnancy

American Journal of Medical Genetics, Part C: Seminars in Medical Genetics

Volumn 157, Issue 3, 2011, Pages 175-182

  Adam, Margaret P ^a   Polifka, Janine E ^a   Friedman, J M ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

BIRTH DEFECTS; DRUG SAFETY; PREGNANCY; SURVEILLANCE; TERATOGEN; TRENDS

Indexed keywords

AMFEBUTAMONE; ATENOLOL; AZITHROMYCIN; BEHENYL ALCOHOL; BUDESONIDE; CAPTOPRIL; CITALOPRAM; CLOMIPRAMINE; CYCLOSPORIN; DICLOFENAC; DRONABINOL; EFAVIRENZ; ENALAPRIL MALEATE; FAMOTIDINE; FOSPROPOFOL; KETOPROFEN; LAMIVUDINE; LAMOTRIGINE; LORATADINE; MESALAZINE; MIRTAZAPINE; MISOPROSTOL; NIFEDIPINE; OLMESARTAN; PANTOPRAZOLE; PROPOFOL; TADALAFIL; TINZAPARIN; UNINDEXED DRUG; VARDENAFIL;

ARTICLE; CASE CONTROL STUDY; DISEASE REGISTRY; DRUG SAFETY; FEMALE; HUMAN; POPULATION RESEARCH; POSTMARKETING SURVEILLANCE; PREGNANCY; PRENATAL EXPOSURE; PRIORITY JOURNAL; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY; TERATOGENICITY; THIRD TRIMESTER PREGNANCY; UNSPECIFIED SIDE EFFECT;

FEMALE; HUMANS; PHARMACEUTICAL PREPARATIONS; PREGNANCY; REGISTRIES; RISK; TERATOGENS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79960563549     PISSN: 15524868     EISSN: 15524876     Source Type: Journal    
DOI: 10.1002/ajmg.c.30313     Document Type: Article

References (39)

1. Alwan S, Polifka JE, Friedman JM. 2005b. Addendum: Sartan treatment during pregnancy. Birth Defects Res A Clin Mol Teratol 73: 904-905.
2. Alwan S, Polifka JE, Friedman JM. 2005a. Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res A Clin Mol Teratol 73: 123-130.
3. Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, McPhillips H, Raebel MA, Roblin D, Smith DH, Yood MU, Morse AN, Platt R. 2004. Prescription drug use in pregnancy. Am J Obstet Gynecol 191: 398-407.
4. Boyd PA, Haeusler M, Barisic I, Loane M, Garne E, Dolk H. 2011. Paper 1: The EUROCAT network: Organization and processes. Birth Defects Res A Clin Mol Teratol 91: S2-S15.
5. Briggs GG, Freeman RK, Yaffe SJ. 2011. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk, 9th edition. Philadelphia: Lippincott Williams & Wilkins.
6. Buhimschi CS, Weiner CP. 2009. Medications in pregnancy and lactation: Part 2. Drugs with minimal or unknown human teratogenic effect. Obstet Gynecol 113: 417-432.
7. Chambers CD. 2011. Value of the small cohort study including a physical examination for minor structural defects in identifying new human teratogens. Congenit Anom (Kyoto) 51: 16-20.
8. Chambers CD, Tutuncu ZN, Johnson D, Jones KL. 2006. Human pregnancy safety for agents used to treat rheumatoid arthritis: Adequacy of available information and strategies for developing post-marketing data. Arthritis Res Ther 8: 215-225 DOI: 10.1186/ar1977.
9. Cohen-Kerem R, Nulman I, Abramow-Newerly M, Medina D, Maze R, Brent RL, Koren G. 2006. Diagnostic radiation in pregnancy: Perception versus true risks. J Obstet Gynaecol Can 28: 43-48.
10. Colvin L, Slack-Smith L, Stanley FJ, Bower C. 2010. Linking a pharmaceutical claims database with a birth defects registry to investigate birth defect rates of suspected teratogens. Pharmacoepidemiol Drug Saf 19: 1137-1150.
11. Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, Hall K, Ray WA. 2006. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 354: 2443-2451.
12. Czeizel AE. 1996. Recommendation to avoid all drugs during first trimester unrealistic. BMJ 313: 424.
13. Ehrenstein V, Sorensen HT, Bakketeig LS, Pedersen L. 2010. Medical databases in studies of drug teratogenicity: Methodological issues. Clin Epidemiol 2: 37-343.
14. Fleiss JL. 1981. Statistical methods for rates and proportions. New York: Wiley.
15. Friedman JM, Little BB, Brent RL, Cordero JF, Hanson JW, Shepard TH. 1990. Potential human teratogenicity of frequently prescribed drugs. Obstet Gynecol 75: 594-599.
16. Friedman JM, Polifka JE. 2011. TERIS. Micromedex Reproductive Risk Information System (REPRORISK). Englewood, Colorado: Thomson MICROMEDEX.
17. Gagne JJ, Maio V, Berghella V, Louis DZ, Gonnella JS. 2008. Prescription drug use during pregnancy: A population-based study in Regione Emilia-Romagna, Italy. Eur J Clin Pharmacol 64: 1125-1132.
18. Gravseth Espnes M, Bjorge T, Engeland A. 2011. Comparison of recorded medication use in the Medical Birth Registry of Norway with prescription medicines registered in the Norwegian Prescription Database. Pharmacoepidemiol Drug Saf 20: 243-248.
19. Hancock RL, Ungar WJ, Einarson A, Koren G. 2010. International practices in the provision of teratology information: A survey of international teratogen information programmes and comparisons with the North American model. J Eval Clin Pract 16: 957-963.
20. Källén Bengt. 1988. Epidemiology of human reproduction. Boca Raton, FL: CRC Press.
21. Koren G. 2002. Ethical framework for observational studies of medicinal drug exposure in pregnancy. Teratology 65: 191-195.
22. Kubicsek T, Kazy Z, Czeizel AE. 2010. Teratogenic potential of tribenoside, a drug for the treatment of haemorrhoids and varicose veins-A population-based case-control study. Reprod Toxicol 31: 464-469.
23. Lo WY, Friedman JM. 2002. Teratogenicity of recently introduced medications in human pregnancy. Obstet Gynecol 100: 465-473.
24. Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernandez-Diaz S, The National Birth Defects Prevention Study. 2011. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol 205: 51.e1-8.
25. Olesen C, Sorensen HT, de Jong-van den Berg L, Olsen J, Steffensen FH. 1999. Prescribing drug pregnancy and lactation with reference to the Swedish classification system. A population-based study among Danish women. The Euromap Group. Acta Obstet Obstet Gynecol Scand 78: 686-692.
26. Polifka JE, Friedman JM. 1999. Clinical teratology: Identifying teratogenic risks in humans. Clin Genet 56: 409-420.
27. Polifka JE, Friedman JM. 2003. Developmental toxicity of ribavirn/IFalpha combination therapy: Is the label more dangerous than the drugs? Birth Defects Res A Clin Mol Teratol 67: 8-12.
28. Rubin JD, Ferencz C, Loffredo C. 1993. Use of prescription and non-prescription drugs in pregnancy. The Baltimore-Washington Infant Study Group. J Clin Epidemiol 46: 581-589.
29. Schaefer C, Peters P, Miller RK, editors. 2007. Drugs during pregnancy and lactation: Treatment options and risk assessment, 2nd edition. Burlington: Academic Press.
30. Scialli AR. 1992. A clinical guide to reproductive and developmental toxicology. Boca Raton: CRC Press.
31. Scialli AR. 1993. Animal studies and human risk. Reprod Toxicol 7: 533-534.
32. Scialli AR, Buelke-Sam JL, Chambers CD, Friedman JM, Kimmel CA, Polifka JE, Tassinari MS. 2004. Communicating risks during pregnancy: A workshop on the use of data from animal developmental toxicity studies in pregnancy labels for drugs. Birth Defects Res A Mol Teratol 70: 7-12.
33. Schardein JL. 2000. Chemically induced birth defects, 3rd edition. New York: Marcel Dekker.
34. Shepard TH. 2010. Catalog of teratogenic agents, 13th edition. Baltimore: The Johns Hopkins University Press.
35. Uhl K, Kennedy DL, Gilliland WR. 2004. Disease modifying anti-rheumatic drugs and pregnancy. J Rheumatol 31: 400-401.
36. Weber-Schoendorfer C, Hannemann D, Meister R, Elefant E, Cuppers-Maarschalkerweerd B, Arnon J, Vial T, Rodriguez-Pinilla E, Clementi M, Robert-Gnansia E, De Santis M, Malm H, Dolivo A, Schaefer C. 2008. The safety of calcium channel blockers during pregnancy: A prospective, multicenter, observational study. Reprod Toxicol 26: 24-30.
37. Webster WS, Freeman JA. 2003. Prescription drugs and pregnancy. Expert Opin Pharmacother 4: 949-961.
38. Werler MM, Mitchell AA, Hernandez-Diaz S, Honein MA. 2005. Use of over-the-counter medications during pregnancy. Am J Obstet Gynecol 193: 771-777.
39. Yoon PW, Rasmussen SA, Lynberg MC, Moore CA, Anerka M, Carmichael SL, Cota P, Durschel C, Hobbs CA, Romitti PA, Langlois PH, Edmonds LD. 2001. The national birth defects prevention study. Public Health Rep 116: 32-40.